On Apr. 15, 2020, Vanda Pharmaceuticals announced initiation of the CALYPSO program to study the role that human genetic variations play in SARS-CoV-2 (COVID-19) infection and disease progression. As a part of theCALYPSO program, Vanda collaborated with University of Washington School of Medicine and its Virology Lab on a pharmacogenetics study inpatients with COVID-19. The study focused on the sequencing of the genome of individual patients, as well as the COVID-19 virus, and theidentification of genetic factors that correlate with disease progression and outcomes.